Ear infection showdown: boric acid vs. povidone iodine
NCT ID NCT07295210
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested two common treatments for fungal ear infections: boric acid and povidone iodine. Sixty patients were treated with one of the two solutions applied directly to the ear canal. The goal was to see which one clears the infection better and reduces symptoms like pain and itching.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- boric acid and povidone iodine
- What this could lead to
- If one treatment works better, it could become a standard, affordable option for fungal ear infections.
- What could go wrong
- This is a small, completed trial with only 60 people. Results may not apply to everyone, and both treatments can cause irritation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
60 people
The number who actually took part.
- Started
-
Dec 2024
- Finished
-
Dec 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * all consecutive patients with otomycosis, recruited from the outpatient clinic during the study duration Exclusion Criteria: * tympanic membrane perforation * previous ear surgery * significant medical co-morbidities such as poorly controlled diabetes or immunocompromised patients * patient refusal to participate in the study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Otomycosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Faculty of Medicine, Mansoura University
Al Mansurah, Dakahlia Governorate, 35511, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.